September 23, 2020
Global Brain has invested in Siolta Therapeutics, Inc., a clinical stage biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases
Global Brain (Global Brain) has invested in Siolta Therapeutics Inc. (Siolta Therapeutics, Founder & CEO: Nikole E. Kimes, PhD), a clinical stage biotech company focused on developing therapeutic microbial consortia to prevent and treat inflammatory diseases, through its Kirin Health Innovation fund （KHIF）and its GB-VII Growth Fund Investment Limited Partnership（GB-VII）.
Siolta Therapeutics leverage their deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases.
Global Brain joined the round of funding which involved participation from top tier investors, including Khosla Ventures, Marc Benioff, Seventure Partners and SymBiosis. Global Brain highly values their unique approaches and technologies of the infant gut microbiome with the inflammatory diseases, its strong management team and its high growth potential. Together with Kirin, Global Brain will continue leveraging its resources to support Siolta Therapeutics by assisting its growth in Asia and global.
Siolta Therapeuticsについて
- Name
- Siolta Therapeutics Inc.
- Location
- San Francisco, CA
- Representative
- Nikole E. Kimes, PhD
- Founded
- February, 2017
About KHIF
- Name
- KIRIN-GB Fund I L.P.
- Fund Term
- 10 years
- Fund Size
- 5 billion JPY
- General Partner
- Global Brain Corporation
About GB-VII
- Name
- GB-VII Growth Fund Investment Limited Partnership
- General Partner
- Global Brain Corporation
About Global Brain
- Name
- Global Brain Corporation
- Location
- Tokyo, Japan
- Representative
- Yasuhiko Yurimoto
- Founded
- January, 1998